Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
HC Wainwright & Co. Maintains Buy Rating for Arrowhead Pharmaceuticals: Here's What You Need To Know
05:00pm, Tuesday, 06'th Dec 2022 Benzinga
HC Wainwright & Co. has decided to maintain its Buy rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) and lower its price target from $110.00 to $90.00.
Shares of Arrowhead Pharmaceuticals are trading
Analyst Ratings for Arrowhead Pharmaceuticals
01:04pm, Tuesday, 29'th Nov 2022 Benzinga
Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
4
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
12:01pm, Tuesday, 29'th Nov 2022
Arrowhead provided a bullish update for its midstage liver disease treatment on Monday, pushing ARWR stock to rocket Tuesday. The post Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2022 Earnings Call Transcript
08:44pm, Monday, 28'th Nov 2022
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q4 2022 Earnings Conference Call November 28, 2022 4:30 PM ET Company Participants Vincent Anzalone - VP, IR Dr. Christopher Anzalone - President and CEO
Arrowhead Pharmaceuticals: Olpasiran's Impressive Phase 2 Data
09:00am, Tuesday, 08'th Nov 2022
Arrowhead's partner Amgen reported positive phase 2 results of olpasiran in patients with elevated Lp[a]. Efficacy of the highest doses is near the maximum with 97% absolute reduction in Lp[a] concent
Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
06:14pm, Monday, 12'th Sep 2022
Arrowhead is an RNA-interference drug developer with a potentially best-in-class platform in TRiM. The company has attracted five major pharmaceutical partners in Janssen, Amgen, Takeda, GSK and Horiz
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
02:40pm, Friday, 09'th Sep 2022 Benzinga
Upgrades
For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform
Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
03:09pm, Tuesday, 23'rd Aug 2022
JNJ tends to announce big news at yearly fall conference, which might be a catalyst for partnered Arrowhead Pharmaceuticals this fall. JNJ's collaboration project with Arrowhead could be ready for Pha
What 7 Analyst Ratings Have To Say About Arrowhead Pharmaceuticals
07:05pm, Monday, 08'th Aug 2022 Benzinga
Analysts have provided the following ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript
04:00am, Friday, 05'th Aug 2022 The Motley Fool
ARWR earnings call for the period ending June 30, 2022.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2022 Results - Earnings Call Transcript
09:59pm, Thursday, 04'th Aug 2022
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2022 Results Conference Call August 4, 2022 5:00 PM ET Company Participants Vince Anzalone - VP, IR Christopher Anzalone - President and CEO Javier Sa
Arrowhead Pharmaceuticals: An RNAi Name To Know
03:45pm, Thursday, 28'th Jul 2022
Shares of RNA interference concern Arrowhead Pharmaceuticals are down over 50% since making an all-time high in June 2021. The company's approach has been validated by its four licensing deals, rival
Growth stocks remain resilient in weakening economy, says Neuberger's Jason Tauber
05:13pm, Friday, 08'th Jul 2022
Jason Tauber, Neuberger Berman large cap disciplined growth and the disruptors portfolio manager, joins 'Closing Bell: Overtime' to discus his bullish case for the growth trade.
5 Top Biotech Stocks To Watch In July 2022
02:30pm, Thursday, 30'th Jun 2022
Amid choppy markets, could there be potential in these top biotech stocks?
Arrowhead Pharma: We Can Afford To Wait For More Proof
11:17am, Tuesday, 28'th Jun 2022
Arrowhead is a leader in RNAi. ARWR has a vast platform.
